Acute respiratory distress syndrome associated with coronavirus infection is related to a
cytokine storm with large interleukin‐6 (IL‐6) release. The IL‐6‐receptor blocker tocilizumab …

The safety and efficacy of tocilizumab for the treatment of severe respiratory symptoms due
to COVID‐19 remain uncertain, in particular among solid organ transplant (SOT) recipients …

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that began
in Wuhan, China, has spread rapidly and has already taken on pandemic proportions. 1 …

In cases of COVID-19 acute respiratory distress syndrome, an excessive host inflammatory
response has been reported, with elevated serum interleukin-6 levels. In this multicenter …

The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a
significant burden on hospitals and healthcare providers. The immune response to this …

The novel coronavirus disease 2019 (COVID‐19) is a highly infectious and rapidly
spreading disease. There are limited published data on the epidemiology and outcomes of …

Background Due to the lack of proven therapies, we evaluated the effects of early
administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab …

Abstract Coronavirus disease 2019 (COVID‐19) due to infection with severe acute
respiratory syndrome coronavirus 2 causes substantial morbidity. Tocilizumab, an …

The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and
are being treated with immunosuppression is unclear. We describe 20 kidney transplant …

The coronavirus disease 2019 (COVID-19) has caused a global pandemic, resulting in
considerable morbidity and mortality. Tocilizumab, an inhibitor of IL-6, has been widely …